Medtronic PLC $MDT Stake Boosted by Continuum Advisory LLC

Continuum Advisory LLC grew its stake in shares of Medtronic PLC (NYSE:MDT) by 24.6% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 31,123 shares of the medical technology company’s stock after acquiring an additional 6,149 shares during the period. Continuum Advisory LLC’s holdings in Medtronic were worth $2,990,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Lodestone Wealth Management LLC purchased a new position in shares of Medtronic during the 4th quarter valued at $27,000. Anfield Capital Management LLC grew its holdings in shares of Medtronic by 410.7% during the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after acquiring an additional 230 shares in the last quarter. Board of the Pension Protection Fund purchased a new position in shares of Medtronic during the 4th quarter valued at $29,000. GoalVest Advisory LLC purchased a new position in shares of Medtronic during the 4th quarter valued at $29,000. Finally, Imprint Wealth LLC bought a new stake in Medtronic in the third quarter worth $31,000. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Medtronic Trading Up 5.1%

Shares of NYSE:MDT opened at $81.95 on Friday. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 1 year low of $73.31 and a 1 year high of $106.33. The firm has a fifty day moving average price of $81.58 and a 200 day moving average price of $92.11. The stock has a market capitalization of $105.22 billion, a PE ratio of 21.97, a P/E/G ratio of 1.89 and a beta of 0.58.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a net margin of 13.20% and a return on equity of 14.61%. The company had revenue of $9.81 billion during the quarter, compared to analysts’ expectations of $9.62 billion. During the same period in the prior year, the company earned $1.62 earnings per share. The business’s quarterly revenue was up 9.9% compared to the same quarter last year. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Analysts expect that Medtronic PLC will post 5.97 EPS for the current fiscal year.

Medtronic Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 17th. Shareholders of record on Friday, June 26th will be issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 3.5%. This is a positive change from Medtronic’s previous quarterly dividend of $0.71. The ex-dividend date is Friday, June 26th. Medtronic’s dividend payout ratio is currently 79.11%.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic beat fiscal Q4 revenue and earnings estimates, driven by strong demand in cardiovascular devices, cardiac ablation, and medical-surgical products, which helped fuel the stock’s rebound.
• Positive Sentiment: The company raised its quarterly dividend to $0.72 per share, signaling confidence in cash generation and rewarding income-focused investors.
• Positive Sentiment: Management highlighted expanded Hugo robotic-assisted surgery filings and FDA activity, suggesting additional growth opportunities in surgical robotics. Medtronic submits 510(k) filings to expand Hugo robotic-assisted surgery system into general and gynecologic specialties in the United States
• Positive Sentiment: Several analysts maintained or upgraded bullish views, including BTIG’s upgrade to Buy and TD Cowen’s reiterated Buy, reinforcing optimism after the earnings beat. Wall Street May Be Mispricing Medtronic, Analyst Says
• Neutral Sentiment: Some analysts trimmed price targets while keeping neutral or hold ratings, including JPMorgan, Piper Sandler, Goldman Sachs, Baird, and Deutsche Bank, which reflects more cautious valuation views rather than a major change in the long-term story.
• Neutral Sentiment: Medtronic is also managing cardiovascular device recalls tied to sterile barrier concerns, creating an ongoing overhang even as newer product launches gain traction.
• Negative Sentiment: FY2027 EPS guidance came in slightly below the consensus estimate, and management noted tariff-related and margin pressure concerns, which may limit further upside. MDT Q4 Earnings Call Points to Another Year of Growth

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Wall Street Zen cut shares of Medtronic from a “buy” rating to a “hold” rating in a report on Saturday, April 11th. Wells Fargo & Company decreased their price objective on shares of Medtronic from $114.00 to $102.00 and set an “overweight” rating for the company in a report on Thursday. UBS Group decreased their price objective on shares of Medtronic from $90.00 to $85.00 and set a “neutral” rating for the company in a report on Thursday. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Medtronic from $100.00 to $78.00 and set a “hold” rating for the company in a report on Thursday. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Medtronic from $100.00 to $86.00 and set a “neutral” rating for the company in a report on Thursday. Sixteen equities research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Medtronic has an average rating of “Moderate Buy” and an average price target of $98.70.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).